Sichuan Zixigong Pharmaceutical Co., Ltd. is a national high-tech enterprise focusing on the research and development, production and marketing of drugs. Zixigong Pharmaceutical currently has 3 subsidiaries and 2 production bases, with 97 drug production approval numbers, tablets, capsules, powders, liniments, ointments, suppositories, tinctures and other dosage forms, artificial beef yellow and benzoic acid Raw materials such as rizatriptan.

Over the years, Ziligong Pharmaceutical has used the enterprise technology center as the new drug research and development center, striving to improve its scientific research capabilities, and has successively developed sodium citicoline tablets, rizatriptan benzoate capsules, pregabalin oral solution, and selai. Many new drug varieties such as Coxibu Capsules. At the same time, the company actively cooperates with many universities and research institutes to establish a new drug innovation research and development platform. The company has obtained 71 patents, including 26 invention patents. The main new drugs that have been launched by Ziligong Pharmaceutical include: sodium citicoline tablets, rizatriptan benzoate capsules, Oriental Gastrophic Acid capsules, pregabalin oral solution, celecoxib capsules, etc. At the same time, Kunming Zishengong Quanxin Biopharmaceutical Co., Ltd., a holding subsidiary located in Shilin County, Kunming City, south of the colorful clouds, also owns the national exclusive ethnic medicine Qingchant Tongue Capsules (Yi Medicine) and Knotweed Pain Tincture (Yi Medicine) , Xuanju Capsules (Dai Medicine) and more than 40 basic and low-priced general medicine varieties with competitive advantages in Yunnan Province.

The company is committed to the development of "new special medicines", with the core competitiveness of creating the research and development and marketing of cost-effective first-line specialty drugs, combining technological innovation and innovation, industry, education and research cooperation, independent research and development with technology introduction, and strives to achieve "Production generation, reserve generation, research and development generation", one by one, and advance layer by layer. The company actively cooperates with Sichuan University West China Pharmaceutical College, Sichuan Academy of Traditional Chinese Medicine Science, Shandong Bainuo Pharmaceutical Co., Ltd. and other universities and research institutes to establish a new drug innovation research and development platform. During the 14th Five-Year Plan period, the Chinese medicine Majiazi, which is under development for the treatment of gastric and colon cancer, obtained clinical trial approval documents; the chemical drug Vidraglitine tablets and oseltamivir phosphate capsules were submitted for production approval documents, and pregabalin oral administration The solution and celecoxib capsules successively obtained production approval documents. The company attaches importance to improving team capabilities, introduces an advanced strategic performance management system - a balanced scorecard, and implements comprehensive strategic performance management. Zixigong Pharmaceutical is rapidly forming a high-tech modern pharmaceutical enterprise focusing on R&D, production and marketing with the advantages of talent, scientific research and marketing.